carbamazepine

carbamazepine is a medication primarily used in the management of epilepsy and neuropathic pain. It is a cornerstone treatment for focal seizures and is also effective for conditions such as trigeminal neuralgia and bipolar disorder. The drug is marketed under various brand names including Tegretol and is listed on the World Health Organization's List of Essential Medicines.

Medical uses

Carbamazepine is a first-line agent for the treatment of focal epilepsy, as endorsed by guidelines from the International League Against Epilepsy. It is also approved for the management of trigeminal neuralgia, a severe facial pain condition, and is used as a mood stabilizer in bipolar disorder, particularly for acute mania. Off-label uses include the treatment of diabetes insipidus and certain psychiatric conditions, though its use is often guided by clinical experience from institutions like the Mayo Clinic. Its efficacy in generalized tonic-clonic seizures is established, but it is generally avoided in other generalized epilepsy types such as absence seizures or myoclonic seizures due to risk of exacerbation.

Adverse effects

Common adverse effects include dizziness, drowsiness, ataxia, nausea, and vomiting. Potentially serious effects require monitoring; these include leukopenia, thrombocytopenia, and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, which are strongly associated with the HLA-B*1502 allele in populations such as those of Han Chinese descent. Other significant risks include hyponatremia, hepatotoxicity, and drug reaction with eosinophilia and systemic symptoms, necessitating regular blood tests as recommended by agencies like the U.S. Food and Drug Administration.

Pharmacology

Carbamazepine exerts its primary therapeutic effect by use-dependent blockade of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive firing. This mechanism is shared with other agents like phenytoin and lamotrigine. It is metabolized primarily in the liver by the cytochrome P450 system, specifically the CYP3A4 isoenzyme, into an active metabolite, carbamazepine-10,11-epoxide. The drug induces its own metabolism via the pregnane X receptor, leading to autoinduction and complex pharmacokinetics studied extensively at institutions like the National Institutes of Health.

Interactions

Carbamazepine is a potent inducer of cytochrome P450 enzymes, particularly CYP3A4, leading to decreased plasma concentrations of many concomitant drugs, including warfarin, doxycycline, theophylline, and many antiretroviral agents. Conversely, inhibitors of CYP3A4, such as erythromycin, cimetidine, and fluoxetine, can increase carbamazepine levels and risk of toxicity. It also decreases the efficacy of hormonal contraception and interacts with other antiepileptic drugs like valproate and phenobarbital, necessitating careful management as outlined in resources like the British National Formulary.

Chemistry

Carbamazepine is a derivative of iminostilbene, with a chemical structure based on the dibenzazepine tricyclic system. It is chemically related to the tricyclic antidepressants such as imipramine. The compound is a white to off-white powder, practically insoluble in water but soluble in organic solvents like ethanol. Its synthesis and stereochemistry have been detailed in publications from the American Chemical Society.

History

Carbamazepine was first synthesized in 1953 by chemist Walter Schindler at the Swiss pharmaceutical company Geigy, now part of Novartis. It was initially investigated for the treatment of trigeminal neuralgia and was introduced for this use in the United States in 1962. Its utility in epilepsy was discovered later, with approval for this indication following in 1974. The drug's development marked a significant advance in neurology and its role was further solidified by large-scale trials such as the Veterans Administration Cooperative Study. Category:Anticonvulsants Category:Dibenzazepines